Edwards Lifesciences (NYSE:EW) SVP Andrew Dahl Sells 568 Shares of Stock

Edwards Lifesciences Corporation (NYSE:EW) SVP Andrew Dahl sold 568 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the sale, the senior vice president directly owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Edwards Lifesciences Stock Up 0.5%

Shares of NYSE:EW opened at $86.41 on Friday. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $88.28. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. The company has a market capitalization of $49.76 billion, a PE ratio of 45.96, a PEG ratio of 2.15 and a beta of 0.87. The company has a 50 day moving average price of $81.73 and a two-hundred day moving average price of $83.01.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. During the same quarter in the prior year, the firm earned $0.64 earnings per share. The business’s quarterly revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Institutional Investors Weigh In On Edwards Lifesciences

Several large investors have recently made changes to their positions in EW. Hanson & Doremus Investment Management bought a new stake in shares of Edwards Lifesciences during the first quarter worth $25,000. JPL Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the third quarter worth $25,000. MV Capital Management Inc. bought a new stake in shares of Edwards Lifesciences during the fourth quarter worth $26,000. RMG Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the first quarter worth $26,000. Finally, Kemnay Advisory Services Inc. bought a new position in Edwards Lifesciences in the fourth quarter valued at $27,000. Institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

EW has been the subject of several recent analyst reports. Piper Sandler reaffirmed an “overweight” rating and issued a $100.00 target price (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. UBS Group reaffirmed a “neutral” rating and issued a $94.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Wells Fargo & Company upped their target price on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. Wolfe Research raised shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price for the company in a research note on Wednesday, April 1st. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $95.00 target price (down from $108.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $95.65.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.